<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472796</url>
  </required_header>
  <id_info>
    <org_study_id>CSPP100AUS41T</org_study_id>
    <nct_id>NCT01472796</nct_id>
  </id_info>
  <brief_title>Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension</brief_title>
  <acronym>VDATH</acronym>
  <official_title>Vitamin D Augmentation of Tekturna (Aliskiren) in Hypertension (VDATH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wayne State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Wayne State University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, the goal is to find out if a currently FDA-approved medication called
      Tekturna(Aliskiren) along with the addition of Vitamin D will lower blood pressure and
      improve heart function in the African American population. High blood pressure occurs earlier
      in life in African Americans, is more severe, and is associated with greater organ damage in
      relation to uncontrolled hypertension. Having low levels of Vitamin D is also very common in
      the African American population. Research has shown that there may be a link between low
      Vitamin D levels and the ability of high blood pressure medications to be fully effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overarching hypothesis is that African Americans with hypertension have an overactive RAS
      (Renin Angiotensin System) in the body that is responsible for internally regulating blood
      pressure. Many blood pressure medications change regulation of the RAS system in order to
      keep blood pressure down. The purpose of this research study is to determine whether or not
      African American adults with hypertension have an overactive RAS system due to Vitamin D
      deficiency, resulting in the inability of the medication Tekturna to lower blood pressure. In
      this study, all participants will receive 300mg of Tekturna per day. Additionally half of the
      participants will randomly be selected to receive either 50,000 IU of Vitamin D (in its
      cholecalciferol form) orally once every other week or a vitamin D placebo once every other
      week. There will be 4 study visits over 18 weeks and follow up phone calls every two weeks
      for the duration of the study.

      Specific Aims:

      To demonstrate in African American Hypertensives consuming a calcium replete diet that
      Tekturna + Vitamin D will lower blood pressure more than Tekturna + placebo.

      To demonstrate in African American hypertensives consuming a calcium replete diet that
      albuminuria will be lowered more with Tekturna + Vitamin D versus Tekturna + placebo.

      To demonstrate in African American hypertensives consuming a calcium replete diet that
      Tekturna + Vitamin D will improve measures on non-invasively measured vascular function
      (peripheral vascular resistance, augmentation index, carotid-femoral pulse wave velocity and
      central aortic pressure) more than Tekturna + placebo.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Ambulatory Systolic Blood Pressure</measure>
    <time_frame>from baseline (Week 10) to Week 18</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in ambulatory diastolic blood pressure</measure>
    <time_frame>from baseline (Week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cuff systolic blood pressure</measure>
    <time_frame>from baseline (Week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in cuff diastolic blood pressure</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Urinary albumin:creatinine ratio</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma isoprostanes</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary nitric oxide metabolites</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma renin activity</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in urinary angiotensinogen</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in non-invasively obtained measures of vascular function</measure>
    <time_frame>from baseline (week 10) to Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Tekturna (Aliskirin) with vit. D supplementation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tekturna (Aliskiren) 300mg daily and vitamin D supplementation (50,000 IU)every other week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tekturna (Aliskiren) with placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Tekturna (Aliskiren) 300mg per day supplemented with placebo (vitamin D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D (cholecalciferol)</intervention_name>
    <description>Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks</description>
    <arm_group_label>Tekturna (Aliskirin) with vit. D supplementation</arm_group_label>
    <other_name>Tekturna (Aliskirin)</other_name>
    <other_name>cholecalciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tekturna(Aliskiren) plus placebo</intervention_name>
    <description>Aliskiren 300 mg per day supplemented with placebo</description>
    <arm_group_label>Tekturna (Aliskiren) with placebo</arm_group_label>
    <other_name>Tekturna (Aliskirin)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 30-74

          -  Systolic Blood Pressure 140-159 mm Hg and Diastolic Blood Pressure &lt;100 OR Diastolic
             Blood Pressure 90-99mm Hg and Systolic Blood Pressure &lt;160mm Hg

          -  Vitamin D deficiency: Serum 25-OH D &gt;= 10 ng/ml (25 nmol/L) to &lt; 20 ng/ml (50 nmol/L)

          -  Not using any antihypertensive medication(s) for the previous 3 months

        Exclusion Criteria:

          -  Cancer(other than skin) known HIV or other medical condition that might limit life
             expectancy.

          -  Pregnant or nursing

          -  Know adverse reactions to DRI's

          -  Hepatitis or liver enzyme elevations &gt; 1.5x normal

          -  Estimated glomerular filtration rate (EGFR) &lt;50 ml/min/1.7m2

          -  Diabetes Mellitus

          -  Serum calcium &gt; 10.5 mg/dl or history of hypercalcemia

          -  History of primary hyperparathyroidism

          -  Sarcoidosis or other granulomatous disease

          -  Taking &gt; 500 mg/d of supplemental elemental calcium

          -  Taking any drugs that decrease absorption of vitamin D, ex:xenical

          -  Taking the drug cyclosporine

          -  Taking any antihypertensive medications in the previous 3 months

          -  History of kidney stones

          -  Planning to move &gt; 50 miles in the next 9 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John M Flack, M.D., M.P.H.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University, TRaCE Research Group</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carol A Muzyk, CCRP</last_name>
    <phone>313-745-2378</phone>
    <email>cmuzyk@med.wayne.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Donna Ford</last_name>
    <phone>888-235-5467</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Wayne State University, 4201 St. Antoine</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol A Muzyk, CCRP</last_name>
      <phone>313-745-2378</phone>
      <email>cmuzyk@med.wayne.edu</email>
    </contact>
    <contact_backup>
      <last_name>Donna Ford</last_name>
      <phone>888-235-5467</phone>
    </contact_backup>
    <investigator>
      <last_name>John M Flack, M.D., M.P.H.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2011</study_first_submitted>
  <study_first_submitted_qc>November 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>November 11, 2011</last_update_submitted>
  <last_update_submitted_qc>November 11, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 16, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wayne State University</investigator_affiliation>
    <investigator_full_name>John M. Flack</investigator_full_name>
    <investigator_title>Chairman, Dept. of Internal Medicine, Wayne State University</investigator_title>
  </responsible_party>
  <keyword>African American</keyword>
  <keyword>Vitamin D deficient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

